Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Status:
Completed
Trial end date:
2018-03-16
Target enrollment:
Participant gender:
Summary
Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only
patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind
placebo-controlled trial in which participants were randomized to receive either deferiprone
or placebo for 18 months, are eligible to enroll.